Blair William & Co. IL Has $339,000 Stock Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Key Points

• Blair William & Co. IL has reduced its holdings in BioMarin Pharmaceutical Inc. by 85.2%, now owning 4,800 shares worth approximately $339,000 after selling 27,542 shares.
• Institutional investors are actively trading, with significant increases in positions from firms like Dodge & Cox (6.1% increase) and AQR Capital Management (114.5% increase) during the fourth quarter.
• Analysts have varied opinions on BioMarin's stock price, with targets ranging from $95.00 to $113.00, reflecting a consensus rating of "Moderate Buy".

Blair William & Co. IL decreased its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 85.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,800 shares of the biotechnology company's stock after selling 27,542 shares during the period. Blair William & Co. IL's holdings in BioMarin Pharmaceutical were worth $339,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Byrne Financial Freedom LLC lifted its stake in BioMarin Pharmaceutical by 4.4% during the first quarter. Byrne Financial Freedom LLC now owns 3,852 shares of the biotechnology company's stock worth $272,000 after purchasing an additional 161 shares during the period. Freedom Investment Management Inc. lifted its stake in BioMarin Pharmaceutical by 3.8% during the fourth quarter. Freedom Investment Management Inc. now owns 5,022 shares of the biotechnology company's stock worth $330,000 after purchasing an additional 184 shares during the period. Xponance Inc. lifted its stake in BioMarin Pharmaceutical by 0.6% during the first quarter. Xponance Inc. now owns 31,877 shares of the biotechnology company's stock worth $2,253,000 after purchasing an additional 202 shares during the period. Farther Finance Advisors LLC lifted its stake in BioMarin Pharmaceutical by 95.9% during the first quarter. Farther Finance Advisors LLC now owns 431 shares of the biotechnology company's stock worth $29,000 after purchasing an additional 211 shares during the period. Finally, Nisa Investment Advisors LLC lifted its stake in BioMarin Pharmaceutical by 5.0% during the first quarter. Nisa Investment Advisors LLC now owns 4,572 shares of the biotechnology company's stock worth $323,000 after purchasing an additional 217 shares during the period. Institutional investors own 98.71% of the company's stock.

BioMarin Pharmaceutical Trading Down 0.8%

BMRN traded down $0.46 during trading on Friday, reaching $57.54. 2,525,461 shares of the company's stock were exchanged, compared to its average volume of 2,488,204. The company's fifty day moving average price is $57.40 and its 200-day moving average price is $61.56. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.60 and a current ratio of 5.56. BioMarin Pharmaceutical Inc. has a fifty-two week low of $52.93 and a fifty-two week high of $94.85. The firm has a market capitalization of $11.05 billion, a PE ratio of 17.07, a P/E/G ratio of 0.74 and a beta of 0.18.

Insider Buying and Selling

In other BioMarin Pharmaceutical news, CAO Erin Burkhart sold 1,786 shares of BioMarin Pharmaceutical stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $59.31, for a total transaction of $105,927.66. Following the completion of the sale, the chief accounting officer owned 14,173 shares of the company's stock, valued at approximately $840,600.63. The trade was a 11.19% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.85% of the company's stock.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Wedbush restated an "outperform" rating and set a $94.00 price target on shares of BioMarin Pharmaceutical in a research note on Tuesday, August 5th. UBS Group lifted their target price on shares of BioMarin Pharmaceutical from $113.00 to $114.00 and gave the company a "buy" rating in a research note on Tuesday, August 5th. JPMorgan Chase & Co. lifted their target price on shares of BioMarin Pharmaceutical from $108.00 to $113.00 and gave the company an "overweight" rating in a research note on Monday, July 14th. Citigroup cut their target price on shares of BioMarin Pharmaceutical from $82.00 to $78.00 and set a "neutral" rating for the company in a research note on Friday, May 2nd. Finally, Guggenheim lifted their target price on shares of BioMarin Pharmaceutical from $101.00 to $106.00 and gave the company a "buy" rating in a research note on Wednesday, August 6th. Six investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, BioMarin Pharmaceutical presently has an average rating of "Moderate Buy" and a consensus price target of $93.17.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.